-
1
-
-
44249120160
-
Biopharmaceutical Approvals in the U.S. Increase
-
July
-
Reichert J. Biopharmaceutical Approvals in the U.S. Increase. Reg. Affairs J. Pharma. July 2004, 1-7.
-
(2004)
Reg. Affairs J. Pharma.
, pp. 1-7
-
-
Reichert, J.1
-
2
-
-
34547696982
-
Monoclonal Antibody Gold Rush
-
Maggon K. Monoclonal Antibody Gold Rush. Curr. Med. Chem. 2007, 14:1978-1987.
-
(2007)
Curr. Med. Chem.
, vol.14
, pp. 1978-1987
-
-
Maggon, K.1
-
3
-
-
84881482645
-
Great Expectations, Biopharmaceutical Industry Expects Success from New Drug Therapies and a Full Product Development Pipeline
-
Thayer A.M. Great Expectations, Biopharmaceutical Industry Expects Success from New Drug Therapies and a Full Product Development Pipeline. Chem. Eng. News 1998, 76:19-31.
-
(1998)
Chem. Eng. News
, vol.76
, pp. 19-31
-
-
Thayer, A.M.1
-
4
-
-
0038576283
-
Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002
-
Reichert J.M., Paquette C. Therapeutic recombinant proteins: Trends in US approvals 1982 to 2002. Curr. Op. Mol. Ther. 2003, 5:139-147.
-
(2003)
Curr. Op. Mol. Ther.
, vol.5
, pp. 139-147
-
-
Reichert, J.M.1
Paquette, C.2
-
7
-
-
84882614502
-
-
Deloitte Thompson Reuters
-
Deloitte Thompson Reuters Is R&D Earning its Investment? 2009, http://www.deloitte.com/assets/Dcom-UnitedKingdom/../UK_LS_RD_ROI.pdf.
-
(2009)
Is R&D Earning its Investment?
-
-
-
8
-
-
77249119567
-
-
Wolters Kluwer, Lippincott Williams & Wilkins, New York
-
Spilker B. Biotechnology, Chapter 12 in Guide to Drug Development, A Comprehensive Review and Assessment 2009, Wolters Kluwer, Lippincott Williams & Wilkins, New York.
-
(2009)
Biotechnology, Chapter 12 in Guide to Drug Development, A Comprehensive Review and Assessment
-
-
Spilker, B.1
-
9
-
-
84882649835
-
Drug Discovery: Large Molecule Drugs
-
(chapter 4)
-
Ng R. Drug Discovery: Large Molecule Drugs. In Drugs, from Discovery to Approval 2009, (chapter 4). 2nd ed.
-
(2009)
In Drugs, from Discovery to Approval
-
-
Ng, R.1
-
10
-
-
84882643413
-
-
Genentech. Biosimilars http://www.gene.com/gene/about/views/followon-biologics.html.
-
Genentech. Biosimilars
-
-
-
12
-
-
84882581190
-
-
Wikipedia. Antibody Structure
-
Wikipedia. Antibody Structure http://en.wikipedia.org/wiki/Antibody%23Structure.
-
-
-
-
13
-
-
0033678468
-
Identification and Biological Activity of the Active Metabolite of Clopidogrel
-
Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Identification and Biological Activity of the Active Metabolite of Clopidogrel. Thromb. Haemost. 2000, 84:891-896.
-
(2000)
Thromb. Haemost.
, vol.84
, pp. 891-896
-
-
Savi, P.1
Pereillo, J.M.2
Uzabiaga, M.F.3
Combalbert, J.4
Picard, C.5
Maffrand, J.P.6
Pascal, M.7
Herbert, J.M.8
-
14
-
-
0025168461
-
The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance
-
Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., Przybeck T.R. The Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance. Arch. Intern. Med. 1990, 150:1881-1884.
-
(1990)
Arch. Intern. Med.
, vol.150
, pp. 1881-1884
-
-
Eisen, S.A.1
Miller, D.K.2
Woodward, R.S.3
Spitznagel, E.4
Przybeck, T.R.5
-
15
-
-
67649094956
-
Eltrombopag, The Discovery of a Second Generation Thrombopoietin-Receptor Agonist
-
Stasi R. Eltrombopag, The Discovery of a Second Generation Thrombopoietin-Receptor Agonist. Exp. Opinion Drug Discov. 2009, 4:85-93.
-
(2009)
Exp. Opinion Drug Discov.
, vol.4
, pp. 85-93
-
-
Stasi, R.1
-
16
-
-
33645775454
-
Immune Mechanisms in Drug Allergy
-
Roujeau J.-C. Immune Mechanisms in Drug Allergy. Allergol. Int. 2006, 55:27-33.
-
(2006)
Allergol. Int.
, vol.55
, pp. 27-33
-
-
Roujeau, J.-C.1
-
17
-
-
41149106199
-
Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check
-
Seitz K., Zhou H. Pharmacokinetic Drug-Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check. J. Clin. Pharmacol. 2007, 47:1104-1118.
-
(2007)
J. Clin. Pharmacol.
, vol.47
, pp. 1104-1118
-
-
Seitz, K.1
Zhou, H.2
-
18
-
-
0035336557
-
New Drug Development in the United States from 1963 to 1999
-
DiMasi J.A. New Drug Development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 2001, 69:286-296.
-
(2001)
Clin. Pharmacol. Ther.
, vol.69
, pp. 286-296
-
-
DiMasi, J.A.1
-
20
-
-
79954460014
-
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
-
article 4
-
Trusheim M.R., Aitken M.L., Berndt E.R. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?. Forum Health Econ. Policy 2010, 13(1). article 4.
-
(2010)
Forum Health Econ. Policy
, vol.13
, Issue.1
-
-
Trusheim, M.R.1
Aitken, M.L.2
Berndt, E.R.3
-
22
-
-
78049467253
-
The importance of New Companies for Drug Discovery: Origins of a Decade of New Drugs
-
Kneller R. The importance of New Companies for Drug Discovery: Origins of a Decade of New Drugs. Nat. Rev. Drug Disc 2010, 9:867-882.
-
(2010)
Nat. Rev. Drug Disc
, vol.9
, pp. 867-882
-
-
Kneller, R.1
-
25
-
-
84882670743
-
-
Grabowski at Duke http://www.fuqua.duke.edu/faculty_research/faculty_directory/grabowski/.
-
Grabowski at Duke
-
-
-
27
-
-
34548324706
-
The Cost of Biopharmaceutical R&D: Is Biotech Different?
-
DiMasi J.A., Grabowski H.G. The Cost of Biopharmaceutical R&D: Is Biotech Different?. Manage. Decis. Econ. 2007, 28:469-479.
-
(2007)
Manage. Decis. Econ.
, vol.28
, pp. 469-479
-
-
DiMasi, J.A.1
Grabowski, H.G.2
-
28
-
-
0037374498
-
The Price of Innovation: New Estimates of Drug Development Costs
-
DiMasi J.A., Hansen R.W., Grabowski H.G. The Price of Innovation: New Estimates of Drug Development Costs. J. Health Econ. 2003, 22:151-185.
-
(2003)
J. Health Econ.
, vol.22
, pp. 151-185
-
-
DiMasi, J.A.1
Hansen, R.W.2
Grabowski, H.G.3
-
29
-
-
77149155968
-
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
-
DiMasi J.A., Feldman L., Seckler A., Wilson A. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs. Clin. Pharmacol. Ther. 2010, 87:272-277.
-
(2010)
Clin. Pharmacol. Ther.
, vol.87
, pp. 272-277
-
-
DiMasi, J.A.1
Feldman, L.2
Seckler, A.3
Wilson, A.4
-
30
-
-
0142121432
-
Trends in Development and Approval Times for New Therapeutics in the United States
-
Reichert J. Trends in Development and Approval Times for New Therapeutics in the United States. Nat. Rev. Drug Discov. 2003, 2:695-702.
-
(2003)
Nat. Rev. Drug Discov.
, vol.2
, pp. 695-702
-
-
Reichert, J.1
-
31
-
-
44449151539
-
Follow-On Biologics: Data Exclusivity and the Balance between Innovation and Competition
-
Grabowski H. Follow-On Biologics: Data Exclusivity and the Balance between Innovation and Competition. Nat. Rev. Drug Discov. 2008, 7:479-488.
-
(2008)
Nat. Rev. Drug Discov.
, vol.7
, pp. 479-488
-
-
Grabowski, H.1
-
32
-
-
84882633628
-
-
BIO CEO & Investor Conference, February 15th, 2011BIO.
-
BIO CEO & Investor Conference, February 15th, 2011BIO.
-
-
-
-
34
-
-
79951662416
-
-
Pharmaceutical Research and Manufacturers of America, PhRMA, Washington, DC
-
Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2010 2010, PhRMA, Washington, DC.
-
(2010)
Pharmaceutical Industry Profile 2010
-
-
-
36
-
-
12144268237
-
Macrotrends in Pharmaceutical Innovation
-
Cohen F.J. Macrotrends in Pharmaceutical Innovation. Nature Rev. Drug Discov. 2005, 4:78-84.
-
(2005)
Nature Rev. Drug Discov.
, vol.4
, pp. 78-84
-
-
Cohen, F.J.1
-
37
-
-
25144518364
-
Financial Anatomy of Biomedical Research
-
Moses H., Dorsey E.R., Matheson D.H.M., Their S.O. Financial Anatomy of Biomedical Research. JAMA 2005, 294:1333-1342.
-
(2005)
JAMA
, vol.294
, pp. 1333-1342
-
-
Moses, H.1
Dorsey, E.R.2
Matheson, D.H.M.3
Their, S.O.4
-
39
-
-
62549135030
-
-
Pharmaceutical Research and Manufacturers of America, PhRMA, Washington, DC
-
Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2008 2008, PhRMA, Washington, DC.
-
(2008)
Pharmaceutical Industry Profile 2008
-
-
-
40
-
-
67650381294
-
-
Pharmaceutical Research and Manufacturers of America, PhRMA, Washington, DC
-
Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2009 2009, PhRMA, Washington, DC.
-
(2009)
Pharmaceutical Industry Profile 2009
-
-
-
42
-
-
0035997958
-
Therapeutic Monoclonal Antibodies: Trends in Development and Approval in the US
-
Reichert J. Therapeutic Monoclonal Antibodies: Trends in Development and Approval in the US. Curr. Opin. Mol. Ther. 2002, 4:110-118.
-
(2002)
Curr. Opin. Mol. Ther.
, vol.4
, pp. 110-118
-
-
Reichert, J.1
-
43
-
-
0000986075
-
Bacitracin: A New Antibiotic Produced by a Member of the B. subtilis Group
-
Johnson B.A., Anker H., Meleney F. Bacitracin: A New Antibiotic Produced by a Member of the B. subtilis Group. Science 1945, 102:376-377.
-
(1945)
Science
, vol.102
, pp. 376-377
-
-
Johnson, B.A.1
Anker, H.2
Meleney, F.3
-
44
-
-
54049134450
-
Peptide Drugs Becoming More Prevalent
-
Glaser V. Peptide Drugs Becoming More Prevalent. GEN Genet. Eng. Biotechnol. News 2008, 28(15). http://www.genengnews.com/gen-articles/peptide-drugs-becoming-more-preva lent/2580/.
-
(2008)
GEN Genet. Eng. Biotechnol. News
, vol.28
, Issue.15
-
-
Glaser, V.1
-
45
-
-
33646565349
-
Peptide Drug Discovery Research Reenergized
-
Peptide Drug Discovery Research Reenergized. GEN Genet. Eng. Biotechnol. News 2006, 26(8). http://www.genengnews.com/gen-articles/peptide-drug-discovery-research-r eenergized/1564/.
-
(2006)
GEN Genet. Eng. Biotechnol. News
, vol.26
, Issue.8
-
-
-
46
-
-
66349097253
-
Opportunities and Challenges of Developing Peptide Drugs in the Pharmaceutical Industry
-
Danho W., Swistok J., Khan W., Chu X.J., Cheung A., Fry D., Sun H., Kurylko G., Rumennik L., Cefalu J., Cefalu G., Nunn P. Opportunities and Challenges of Developing Peptide Drugs in the Pharmaceutical Industry. Adv. Exp. Med. Biol. 2009, 611:467-469.
-
(2009)
Adv. Exp. Med. Biol.
, vol.611
, pp. 467-469
-
-
Danho, W.1
Swistok, J.2
Khan, W.3
Chu, X.J.4
Cheung, A.5
Fry, D.6
Sun, H.7
Kurylko, G.8
Rumennik, L.9
Cefalu, J.10
Cefalu, G.11
Nunn, P.12
-
47
-
-
15544379805
-
Watching Peptide Drugs Grow Up
-
Christian N. Watching Peptide Drugs Grow Up. Chem. Eng. News 2005, 83:17-24.
-
(2005)
Chem. Eng. News
, vol.83
, pp. 17-24
-
-
Christian, N.1
-
48
-
-
78650185495
-
Design and Development of Peptides and Peptide Mimetics as Antagonists for Therapeutic Intervention
-
Mason J.M. Design and Development of Peptides and Peptide Mimetics as Antagonists for Therapeutic Intervention. Future Med. Chem 2010, 2:1813-1822.
-
(2010)
Future Med. Chem
, vol.2
, pp. 1813-1822
-
-
Mason, J.M.1
-
51
-
-
70449686823
-
Balancing Innovation, Access, and Profits-Market Exclusivity for Biologics
-
Engelberg A.B., Kesselheim A.S., Avorn J. Balancing Innovation, Access, and Profits-Market Exclusivity for Biologics. N. Engl. J. Med. 2009, 361:1917-1919.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1917-1919
-
-
Engelberg, A.B.1
Kesselheim, A.S.2
Avorn, J.3
-
52
-
-
84882571776
-
-
Effective Health Care, 08-EHC004-2A, April 2008, AHRQ Publication
-
Effective Health Care Rheumatoid Arthritis Medicines, A Guide for Adults, Agency for Healthcare Research and Quality 2008, 08-EHC004-2A, April 2008, AHRQ Publication. http://www.rheumatology.org/practice/clinical/patients/medications/biolo gics.pdf.
-
(2008)
Rheumatoid Arthritis Medicines, A Guide for Adults, Agency for Healthcare Research and Quality
-
-
-
53
-
-
84882676817
-
Biotechnology
-
Wolters Kluwer, Lippincott Williams & Wilkins, New York, (chapter 98)
-
Spilker B. Biotechnology. Guide to Drug Development, A Comprehensive Review and Assessment 2009, 993-1006. Wolters Kluwer, Lippincott Williams & Wilkins, New York, (chapter 98).
-
(2009)
Guide to Drug Development, A Comprehensive Review and Assessment
, pp. 993-1006
-
-
Spilker, B.1
-
54
-
-
54049152026
-
The GPIIb/IIIa (integrin {alpha}IIb{beta}3) Odyssey: A Technology-Driven Saga of a Receptor With Twists, Turns, and Even a Bend
-
Coller B.S., Shattil S.J. The GPIIb/IIIa (integrin {alpha}IIb{beta}3) Odyssey: A Technology-Driven Saga of a Receptor With Twists, Turns, and Even a Bend. Blood 2008, 112:3011-3025.
-
(2008)
Blood
, vol.112
, pp. 3011-3025
-
-
Coller, B.S.1
Shattil, S.J.2
-
55
-
-
0032728451
-
Development of Eptifibatide
-
Scarborough R. Development of Eptifibatide. Am. Heart J. 1996, 1093-1104.
-
(1996)
Am. Heart J.
, pp. 1093-1104
-
-
Scarborough, R.1
-
56
-
-
0027096411
-
Non-peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors
-
Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J. Non-peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35:4640-4642.
-
(1992)
J. Med. Chem.
, vol.35
, pp. 4640-4642
-
-
Hartman, G.D.1
Egbertson, M.S.2
Halczenko, W.3
Laswell, W.L.4
Duggan, M.E.5
Smith, R.L.6
Naylor, A.M.7
Manno, P.D.8
Lynch, R.J.9
-
57
-
-
0037118664
-
Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?
-
Quinn M.J., Plow E.F., Topol E.J. Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?. Circulation 2002, 106:379-385.
-
(2002)
Circulation
, vol.106
, pp. 379-385
-
-
Quinn, M.J.1
Plow, E.F.2
Topol, E.J.3
-
59
-
-
77955479798
-
The Glycoprotein IIb/IIIa Inhibitor Wars, An Update
-
Berger P. The Glycoprotein IIb/IIIa Inhibitor Wars, An Update. J. Am. Coll. Card. 2010, 56:476-478.
-
(2010)
J. Am. Coll. Card.
, vol.56
, pp. 476-478
-
-
Berger, P.1
-
60
-
-
33846278358
-
HER2 Inhibition: From Discovery to Clinical Practice
-
Chang J.C. HER2 Inhibition: From Discovery to Clinical Practice. Clin. Cancer Res. 2007, 13:1-3.
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1-3
-
-
Chang, J.C.1
-
61
-
-
34447498580
-
-
Moy, B., Kirkpatrick, P., Kar, S., and Goss, P. Lapatinib, Nat. Rev. Drug Discov., 6, 431-432.
-
Lapatinib, Nat. Rev. Drug Discov
, vol.6
, pp. 431-432
-
-
Moy, B.1
Kirkpatrick, P.2
Kar, S.3
Goss, P.4
-
62
-
-
77949884661
-
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
-
Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. J. Clin. Oncol. 2010, 28:1124-1130.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1124-1130
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.4
Sledge, G.5
Koehler, M.6
Ellis, C.7
Casey, M.8
Vukelja, S.9
Bischoff, J.10
Baselga, J.11
O'Shaughnessy, J.12
-
67
-
-
78649697382
-
Hearing Shines Spotlight on Biosimilar Controversies
-
Mullard A. Hearing Shines Spotlight on Biosimilar Controversies. Nat. Rev. Drug Discov. 2010, 9:905-906.
-
(2010)
Nat. Rev. Drug Discov.
, vol.9
, pp. 905-906
-
-
Mullard, A.1
|